Travere Therapeutics

Company snapshot

Our mission is to identify, develop and deliver life-changing therapies to people living with rare disease. #InRareForLife Community Guidelines: https://travere.com/community-guidelines/

• 2 approved product(s) across US/EU regulatory metadata.
• 13 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Travere Therapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Travere Therapeutics.

1. Jun 8, 2026 Clinical update

   TVTX-TVT058-301 — Phase 3

2. Jun 8, 2026 Clinical update

   RTRX-RE021-201 — Phase 2

3. Jun 8, 2026 Clinical update

   021IGAN17001 — Phase 3

4. Jun 8, 2026 Clinical update

   021FSGS16010 — Phase 3

5. May 23, 2026 Clinical update

   Fosmetpantotenate — Phase 3

View all clinical trial activity →

• What is Travere Therapeutics?

  Travere Therapeutics is a pharma organization headquartered in San Diego, USA. It trades on NYSE under ticker TVTX. Primary therapeutic focus areas include Focal Segmental Glomerulosclerosis, Immunoglobulin A Nephropathy (IgAN), Classical Homocystinuria, Focal segmental glomerulo

• Is Travere Therapeutics publicly traded?

  Yes. Travere Therapeutics is listed with ticker TVTX on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Travere Therapeutics develop or market?

  We link 9 drug profile(s) where Travere Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/travere-therapeutics#company-drugs.

• What are the latest developments for Travere Therapeutics?

  In the last 12 months our linked public records show 13 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Travere Therapeutics focus on?

  Travere Therapeutics focuses on Focal Segmental Glomerulosclerosis, Immunoglobulin A Nephropathy (IgAN), Classical Homocystinuria based on our analysis of their pipeline programs and drug development activities.